Quantisnow Logo
Dashboard

TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024

$TMDX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $TMDX alert in real time by email

ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (844) 481-2832 for domestic callers or (412) 317-1852 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:

Brian Johnston

332-895-3222

Investors@transmedics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-third-quarter-2024-financial-results-on-october-28-2024-302276974.html

SOURCE TransMedics Group, Inc.

Get the next $TMDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TMDX

DatePrice TargetRatingAnalyst
12/17/2024$116.00 → $75.00Overweight → Neutral
Analyst
11/22/2024Buy → Hold
Needham
10/29/2024$200.00 → $125.00Outperform
Oppenheimer
10/29/2024$208.00 → $109.00Buy
Needham
9/24/2024$200.00Outperform
Robert W. Baird
8/21/2024$208.00Buy
Needham
6/6/2024$161.00Overweight
Cantor Fitzgerald
6/4/2024$151.00Overweight
Stephens
More analyst ratings

$TMDX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results

    ANDOVER, Mass., Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024. Recent Highlights  Total revenue of $121.6 million in the fourth quarter of 2024, a 50% increase compared to the fourth quarter of 2023Total revenue of $441.5 million in the full year of 2024, an 83% increase compared to the full year 2023Generated net income of $

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • TransMedics to Present at Upcoming March Investor Conferences

    ANDOVER, Mass., Feb. 18, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston on Monday, March 3, 2025, at 11:50 a.m. EST and virtually at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference on Monday, March 17, 2025, at 9:20 a.m. EST.

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • TransMedics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

    ANDOVER, Mass., Feb. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844)

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$TMDX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TMDX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TMDX
 SEC Filings

See more

$TMDX
 Leadership Updates

Live Leadership Updates

See more

  • TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

    ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

    NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

    $CCRN
    $CHK
    $ENSG
    $SITC
    Professional Services
    Consumer Discretionary
    Oil & Gas Production
    Energy

  • TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary

    ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$TMDX
 Financials

Live finance-specific insights

See more

  • TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results

    ANDOVER, Mass., Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024. Recent Highlights  Total revenue of $121.6 million in the fourth quarter of 2024, a 50% increase compared to the fourth quarter of 2023Total revenue of $441.5 million in the full year of 2024, an 83% increase compared to the full year 2023Generated net income of $

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • TransMedics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

    ANDOVER, Mass., Feb. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844)

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • TransMedics Reports Third Quarter 2024 Financial Results

    ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023Generated net income of $4.2 million or $0.12 per diluted share in the third quarter of 2024Owned 18 total aircraft as of September 30, 2024

    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$TMDX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more